ESMO Congress 2022 reported pooled survival analysis of the MONALEESA‐2, ‐3, and ‐7 trials in HR‐positive, HER2‐negative breast cancer patients with visceral metastases, including those with liver metastases. This evidence concerns the gene ERBB2 and breast carcinoma.